7 news items
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEVA
1 Jun 24
with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
TEVA
8 May 24
.
The long-term safety of TEV-‘749 and the incidence of post-injection delirium/sedation syndrome (PDSS) are also being evaluated in the SOLARIS open
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEVA
8 May 24
.
Announced positive Phase 3 efficacy results for olanzapine LAI (TEV' 749); no incidence of post-injection delirium
Teva Pharmaceuticals And Medincell Say Phase 3 Efficacy Results From SOLARIS Trial For Schizophrenia Showed That TEV-'749 Met Its Primary Endpoint As Measured By A Change In The PANSS Total Score From Baseline After 8 Weeks Compared To Placebo
TEVA
8 May 24
severity
TEV-‘749 was well tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date: additional
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
TEVA
8 May 24
TEV-‘749 was well tolerated, with no incidence of post-injection delirium
ippz427q91 z3fy8ngouuv0zg2rzavw9oa71rz4fy3
TEVA
11 Apr 24
, Hu L, Wu J. Secular Trends in the Incidence of Migraine in China from 1990 to 2019: A Joinpoint and Age-Period-Cohort Analysis. J Pain Res. 2022 Jan
jnhykgryf9xi
TEVA
6 Apr 24
of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke
- Prev
- 1
- Next